Cyted Health raises $44M for cancer detection tech

💰 ABK Biomedical Inc. secured an oversubscribed $35M Series D led by J.P. Morgan, with continued support from F-Prime, Santé Ventures, Eight Roads Ventures, and a major undisclosed strategic investor. The funding will support ABK’s FDA IDE Route90 trial, advance the upcoming launch of Eye90 microspheres for liver cancer, and scale manufacturing and supply chain operations. 👉 Read more: https://lnkd.in/dJYb4wyT #MedTech #Oncology #Funding #SeriesD #GSCapitalConnect

Today, we announced positive data from our Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers, including data to support the planned launch of our pivotal study in second line MTAP-del #pancreaticcancer next year. In addition, we raised $225M in a concurrent financing supported by leading #biotech investors. Thank you to all Tango associates, scientific founders, collaborators, investigators, and especially the patients who are participating in our ongoing trial and helped us get to this landmark day. The full press release can be found here: https://lnkd.in/e6u7Ea93

Trogenix, a Scottish biotech company developing cutting-edge cancer therapies, has raised €80 million in Series A funding to progress its pipeline aimed at treating aggressive solid tumors. The round was led by IQ Capital and included participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the Brain Tumor Investment Fund, along with new investors Eli Lilly and Company, Meltwind, LongeVC, Calculus Capital, and other undisclosed private investors. Ken Macnamara | Max Bautin | Iain Foulkes | Dima Kuzmin | Steve Pollard | Ken Macnamara | 🔗 Read full article link in comment #Trogenix #Biotech #CancerResearch #PrecisionMedicine #GeneTherapy #Oncology #Innovation #HealthcareTech #LifeSciences #SeriesAFunding #MedicalResearch #EdinburghBiotech #NextGenTherapies #funding #eustartups #news

Predicta Biosciences has raised $23.4 million in a Series A round, led by Engine Ventures, to scale its blood cancer and autoimmune disease diagnostics platform. The funds will support commercialisation of its first test, GenoPredicta, expand its CLIA-certified lab, and develop new noninvasive diagnostics. GenoPredicta uses whole-genome sequencing to assess blood or bone marrow for actionable DNA changes, helping doctors better understand multiple myeloma patients and predict treatment responses. Congratulations to Brian McKernan, François Aguet, Elizabeth Holland, and the rest of the team on this major milestone for Predicta Biosciences

We’re honored to announce the recent completion of a $28 million Series B+ financing round. The round was led by Bayland Capital, with participation from GTJA Investment Group, Proxima Ventures, and existing investors Lapam Capital and Grains Valley Venture Capital. Proceeds from the financing will be used to advance BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase 2. The funding will also support the company’s second program, expected to enter the clinic in 2027, and accelerate the development of additional programs in oncology and autoimmune diseases. In addition, the financing enhances BridGene’s capacity to expand strategic collaborations and further validate the broad applicability of its proprietary IMTAC™ chemoproteomic platform across oncology, immunology, and neurology. Read more here:https://lnkd.in/d5ndNC6v #BridGeneBiosciences #SeriesBRound #BiotechFunding #DrugDiscovery #Chemoproteomics #IMTACPlatform #CovalentInhibitors #TEADInhibitor #Oncology #AutoimmuneDiseases #HardToDrugTargets #SanJose #BayAreaBiotech #LifeSciences #PharmaInnovation #DrugDiscovery #SmallMoleculeDrugs #Chemoproteomics

Tubulis Raises $361 Million to Advance Next-Gen Antibody-Drug Conjugates for Cancer Treatment https://lnkd.in/dEA-mYcw Dr. Dominik Schumacher Dr. Andreas Maurer VENROCK HEALTHCARE CAPITAL PARTNERS LP Wellington Management Ascenta Capital #Tubulis #CancerResearch #ADCs #Biotech #Oncology #LifeSciences #DrugDiscovery #SeriesCFunding #PharmaInnovation #HealthTech

Hear from Liz Correa, PMP, Director, Customer Success Service and Support on how the Yunu platform supports both fast, full-team onboarding for smaller sites and phased rollouts for larger institutions, such as City of Hope, with hundreds of trials. Watch the full-length video here: https://zurl.co/xaiHH #ClinicalTrials #Oncology #CancerResearch #Imaging #Innovation #ClinicalTrialImagingWorkflow #ClinicalTrialImaging #OncologyResearch #DataIntegrity #LifeSciences

Hear from Matthew Bush, Executive Director, Research Applications & Data Management at City of Hope as he shares how strong leadership and strategic outsourcing helped manage high imaging volumes during a major implementation phase. Watch the full panel here: https://zurl.co/OxcR8 #ClinicalTrials #Oncology #CancerResearch #Imaging #Innovation #ClinicalTrialImagingWorkflow #ClinicalTrialImaging #OncologyResearch #DataIntegrity #LifeSciences

Inaphaea BioLabs' Head of Scientific Operations, Melissa Barr, Lead Scientist Amelia Hatfield and Michelle Barnard, Director of Research at parent company, VALIRX PLC, are attending the ELRIG Drug Discovery conference next week in Liverpool. Poster #5, a collaboration between Melissa and Amelia, will be presented during the event. Titled 'Advancing Triple-Negative Breast Cancer Models: From 2D Culture to Patient-Derived 3D Microfluidics', the poster also features work from our collaboration partner, ScreenIn3D, utilising their proprietary UpScale3D lab-on-a- chip technology to create a cost-effective and high-quality, large-throughput and data-rich assays. If you're attending the event and you'd like to speak with Melissa and Michelle about our expertise and services, please get in touch: https://lnkd.in/gjWnzYYe #Assays #AssayDevelopment #ELRIGDD #ELRIGDD25 #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking

Explore the game-changing advancements by Race Oncology, whose breakthrough composition of matter IP has redefined the commercial potential for cancer treatments. Learn how this impactful discovery has fueled investor confidence and sparked a new phase of global expansion for this biotech leader. Discover the details in our latest analysis! When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question: What just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation. Click the link below to read more! https://lnkd.in/g3JD23db #BiotechBreakthrough #InvestorInsights #CancerTherapy #samso #samsonews #samsoaustralia #coffeewithsamso #samsoinsights #asx #raceoncology #RAC